Targeting Lewy Bodies Specific Pathology Using Biomarkers
Study for older adults with dementia with lewy bodies (DLB) to develop early detection methods
Sponsor: NIH
Enrolling: Male and Female Patients
Study Length: 4 Years
Clinic Visits: 6
IRB Number: AAAR0701
Contact: Helen Mejia-Santana: 212-305-9183 / hm28@cumc.columbia.edu
Additional Study Information: The aim of this study is to develop better biomarkers for the diagnosis and treatment of Lewy Body disorders. In particular, there is a need to understand how the contribution of coexisting Alzheimer's disease may affect the diagnosis and clinical course of Lewy Body disorders. This study will recruit a group of individuals with Lewy Body disorders causing cognitive impairment or dementia. Participants will have up to 4-5 visits over 3.5 years. Participants will have a comprehensive neurological evaluation, cognitive and behavior tests, and will donate blood, urine, and cerebrospinal fluid samples.
Investigator
Karen Marder, MD, MPH
Do You Qualify?
Have you been diagnosed with dementia with Lewy bodies (DLB) or Parkinson's disease with cognitive changes? Yes No
Do you speak English or Spanish? Yes No
Are you able to provide consent to participate in the study at the first visit? Yes No
Are you 18 or older? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Helen Mejia-Santana
hm28@cumc.columbia.edu
212-305-9183
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE